Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a Phase I/II study - Kelley, R K; Sangro, B; Harris, W (J Clin Oncol, 2021)